Welcome to Trendlines
We invest in, incubate, and support early-stage, high-promise medical and agricultural technology companies in Israel, a global leader in start-up ingenuity. Read More >
Subscribe to Our Newsletter
Stay in Touch
Editor’s note: The announcement about Trendlines IPO received significant attention in the media. Selected articles appeared in Straits Times, Next Insight, Business Times, Deal Street Asia, Channel News Asia, May Bank Kim Eng (video interview), Globes, and The Marker (Hebrew).
The Trendlines Group announced on November 26, 2015, that further to the launch of its initial public offering (“IPO”) on the Catalist of the Singapore Exchange Securities Trading Limited (“SGX-ST”) on 16 November 2015, the placement of the IPO shares has been successfully completed. The Company is trading on ticker SGX:42T.
Trendlines offered 75,760,000 placement shares at S$0.33 per share, which was approximately 1.4 times price-to-book of Trendlines’ net tangible assets value as at 30 June 2015.
Trendlines received strong interest from investors during the road show, and indications of interests from investors significantly exceeded the number of shares offered. A total of S$25 million (US$17.7 million*) was raised, including S$7.1 million (US$5.0 million) from cornerstone investor B. BRAUN Melsungen AG (“B. BRAUN”), a healthcare supplier with global sales of healthcare products of €5.43 billion.
In the pre-IPO stage, Trendlines raised S$13.7 million (US$9.7 million) from investors, bringing total IPO-related proceeds to S$38.7 million (US$27.4 million).
Commenting on the successful placement of the IPO shares, D. Todd Dollinger, Co-Chairman and CEO of Trendlines, said, “It was encouraging to see the interest from investors. While Trendlines’ business model is unusual compared to most of the listed companies in Singapore, investors understood Trendlines’ ability to incubate technology-based companies in the medical and agricultural fields, bring them to commercialization, and achieve significant returns for investors. The value of investing in Trendlines is well validated by cornerstone investor B. Braun’s strategic investment in us.”
Steve Rhodes, Co-Chairman and CEO of Trendlines, added, “We believe that this successful placement establishes a great start for Trendlines’ trading on the Catalist of SGX-ST. The additional funds build Trendlines’ strong financial position, providing the flexibility to make follow-on investments in portfolio companies, expand into new markets, grow Trendlines Labs, and support and increase the number of portfolio companies.”
The trading of Trendlines’ shares on Catalist commenced at 9:00 a.m. on 26 November 2015. PrimePartners Corporate Finance Pte. Ltd. is the sponsor, issue manager and placement agent for the IPO.
*All currency conversion in the press release is based on USD/SGD of 1.41 as of 20 November 2015.